Shares of TG Therapeutics (TGTX - Get Report) were climbing over 5% during midday trading on Tuesday after the firm announced a successful outcome from its pre-planned interim analysis for its UNITY-CLL Phase 3 trial.
The analysis was conducted by the Data and Safety Monitoring Board (DSMB) which found no safety concerns and recommended continuation of enrollment without modification in a trial.
TG Therapeutics affirmed the study would continue in a 1:1 ratio to only two combination arms. The firm is expecting full enrollment by the end of the year.
UNITY-CLL is used in patients with untreated and previously treated chronic Lymphocytic Leukemia.
Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP's efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.